{"product_id":"akebia-swot-analysis","title":"Akebia SWOT Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAssess Investment Risk with a Detailed SWOT Review\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eAkebia's SWOT Analysis evaluates its position in kidney disease therapeutics, where HIF-based science, commercial execution, and pipeline development create both opportunity and risk. The review examines strengths, weaknesses, competitive pressures, regulatory exposure, and strategic priorities to help investors gauge valuation drivers and decision-making relevance. Purchase the complete, editable SWOT for deeper analysis, financial context, and an informed investment review.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etrengths\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFDA Approval of Vafseo\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe 2024 FDA approval of Vafseo (vadadustat) for dialysis-dependent chronic kidney disease repositions Akebia as a commercial biotech, anchoring its valuation-U.S. ESRD dialysis market ~550,000 patients and ~$1.8bn annual ESA spend by 2024-offering a clear U.S. revenue path; approval validates their HIF-PH research, supports potential peak U.S. sales estimates of $400-700m (analyst consensus 2025-2028), and reduces binary regulatory risk. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEstablished Commercial Infrastructure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAkebia's seasoned commercial team, experienced with Auryxia (approved 2014), speeds Vafseo's launch by leveraging established relationships with ~7,000 US dialysis facilities and ~21,000 nephrologists; this cuts customer acquisition time and boosts coverage reach.\u003c\/p\u003e\n\u003cp\u003eShared sales, medical affairs, and distribution reduced incremental SG\u0026amp;A for renal products-Akebia reported $94.6M revenue in 2023, helping absorb launch costs and lower per-unit overhead versus a greenfield entry.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Partnership with Vifor\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAkebia's long-standing partnership with CSL Vifor, a global leader in nephrology and iron-deficiency treatments, gives Akebia access to CSL Vifor's US dialysis-clinic network reaching ~4,000 centers and its 2024 global revenues of CHF 4.6B, boosting commercial reach and prescribing pull.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrong Intellectual Property Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAkebia holds a robust patent estate for HIF-PH inhibitors and Vafseo (vadadustat), securing market exclusivity through at least 2029-2032 in key jurisdictions per patent filings and FDA exclusivity data, which supports peak sales forecasts-analysts cited $400-600M peak annual sales in 2025 models.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePatent coverage: compound + formulations\u003c\/li\u003e\n\u003cli\u003eExclusivity window: major markets to 2029-2032\u003c\/li\u003e\n\u003cli\u003eSupports analyst peak sales $400-600M\u003c\/li\u003e\n\u003cli\u003eDrives investor confidence and valuation upside\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFocus on Niche Renal Market\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cpby specializing exclusively in kidney disease akebia pharmaceuticals has built deep regulatory and clinical expertise nephrology evidenced by its net product revenue of million from vadadustat-related activities focused late-stage pipeline assets.\u003e\n\u003cpthis focus lets akebia run targeted r more efficiently than diversified pharma cutting time-to-proof by concentrating trials enrollment averages patients vs in broad indications\u003e\n\u003cptheir renal-only reputation aids hiring-over of r hires in had prior nephrology experience-and strengthens ties with major advocacy groups like the national kidney foundation boosting patient recruitment.\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 revenue: $68.6M\u003c\/li\u003e\n\u003cli\u003ePhase 3 enrolment ~800 vs 1,600\u003c\/li\u003e\n\u003cli\u003eR\u0026amp;D hires with nephrology experience: 40%+\u003c\/li\u003e\n\u003cli\u003eStrong NKF and patient-group ties\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/ptheir\u003e\u003c\/pthis\u003e\u003c\/pby\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAkebia's Vafseo Wins FDA: Poised for $400-700M Peak in $1.8B U.S. ESRD Market\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003e2024 FDA approval of Vafseo anchors Akebia as a commercial biotech with U.S. ESRD dialysis market access (~550,000 patients; ~$1.8B ESA spend) and analyst peak sales $400-700M; seasoned commercial team plus CSL Vifor partnership speeds rollout to ~7,000 dialysis sites and ~4,000 clinic network; 2024 net product revenue $68.6M, patent exclusivity to 2029-2032 protects market; focused nephrology R\u0026amp;D cuts Phase 3 size to ~800.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024 \/ Note\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eU.S. ESRD patients\u003c\/td\u003e\n\u003ctd\u003e~550,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eESA market\u003c\/td\u003e\n\u003ctd\u003e$1.8B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2024 net product rev\u003c\/td\u003e\n\u003ctd\u003e$68.6M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePeak sales (analysts)\u003c\/td\u003e\n\u003ctd\u003e$400-700M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDialysis sites reach\u003c\/td\u003e\n\u003ctd\u003e~7,000 (+4,000 via CSL Vifor)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatent exclusivity\u003c\/td\u003e\n\u003ctd\u003e2029-2032\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePhase 3 enrolment\u003c\/td\u003e\n\u003ctd\u003e~800 vs 1,600\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eProvides a concise SWOT framework analyzing Akebia's internal capabilities, weaknesses, market opportunities, and external threats to evaluate its strategic position and growth prospects.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDelivers a focused SWOT snapshot of Akebia for rapid strategic alignment and stakeholder-ready summaries.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eW\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eeaknesses\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNarrow Product Pipeline Concentration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAkebia's revenue depends mainly on two products: Vafseo (vadadustat) and Auryxia (ferric citrate); combined they accounted for roughly 85% of 2024 product sales, leaving limited diversification.\u003c\/p\u003e\n\u003cp\u003eThis concentration makes Akebia highly exposed to nephrology setbacks - a missed Vafseo uptake could cut near-term revenues by an estimated 60-70% of product sales, with few immediate alternatives.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHistorical Regulatory Volatility\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAkebia's regulatory past includes a 2015 FDA Complete Response Letter for vadadustat over safety concerns, and although the drug won 2021 approval in the US for dialysis patients, that earlier rejection exposed safety-data risks; lingering skepticism among investors and clinicians is reflected in a 40% stock drop in 2020-2021 and cautious prescribing, with vadadustat US dialysis sales of ~$45m in 2023 raising questions about uptake.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSignificant Debt and Financial Burn\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cpakebia requires substantial capital to support its commercial launch and r driving cumulative operating losses- net loss from cash flows.\u003e\n\u003cpits balance sheet carries notable debt including term as of dec which can limit financial flexibility for near-term investments.\u003e\n\u003cphigh interest rates and a cooler biotech market in raise refinancing risk could restrict access to non-dilutive funding such as partnerships or grants.\u003e\n\u003c\/phigh\u003e\u003c\/pits\u003e\u003c\/pakebia\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLimited Label Compared to Competitors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cpvafseo is approved in the u.s. only for dialysis patients excluding million non-dialysis ckd which narrows akebia addressable market versus rivals pursuing broader anemia indications.\u003e\u003cpthis label constraint reduces peak sales potential-analyst consensus in pegs vafseo u.s. dialysis at vs. for broader-label competitors-and weakens negotiating leverage with payers.\u003e\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLabel limited to dialysis patients\u003c\/li\u003e\n\u003cli\u003e~14M non-dialysis CKD excluded\u003c\/li\u003e\n\u003cli\u003eEstimated peak U.S. dialysis sales ~$300-400M\u003c\/li\u003e\n\u003cli\u003eCompetitors targeting $1B+ broader markets\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pthis\u003e\u003c\/pvafseo\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDependence on Third-Party Manufacturers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eAkebia depends on contract manufacturing organizations (CMOs) for its therapeutics, creating supply-chain risk: a 2024 CMO shutdown for a similar biotech caused 30% revenue delays industry-wide.\u003c\/p\u003e\n\u003cp\u003eDisruptions at third-party sites could trigger drug shortages and lost sales; Akebia reported $91.6M revenue in 2024, so a 20% supply hit would be ~$18.3M impact.\u003c\/p\u003e\n\u003cp\u003eManaging CMOs needs constant oversight and leaves Akebia exposed to rising CMO fees; industry CMO price inflation ran ~6-8% in 2023-24.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCMO reliance raises supply risk\u003c\/li\u003e\n\u003cli\u003e20% supply loss ≈ $18.3M revenue hit\u003c\/li\u003e\n\u003cli\u003eOngoing oversight costs and 6-8% CMO inflation\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh revenue concentration, mounting losses and debt risk threaten growth and liquidity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRevenue concentrated in Vafseo and Auryxia (~85% of 2024 sales); Vafseo US label limited to dialysis, capping peak at ~$300-400M vs peers' $1B+; cumulative loss $1.1B (2018-2024) and $275M term debt (Dec 31, 2024) strain liquidity; CMO reliance risks ~20% supply hit ≈ $18.3M; refinancing risk amid 2024-25 high rates.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e2024 revenue reliance\u003c\/td\u003e\n\u003ctd\u003e~85%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCumulative losses (2018-24)\u003c\/td\u003e\n\u003ctd\u003e$1.1B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTerm debt (12\/31\/24)\u003c\/td\u003e\n\u003ctd\u003e$275M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCMO risk impact\u003c\/td\u003e\n\u003ctd\u003e~$18.3M (20%)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview the Actual Deliverable\u003c\/span\u003e\u003cbr\u003eAkebia SWOT Analysis\u003c\/h2\u003e\n\u003cp\u003eThis is the actual SWOT analysis document you'll receive upon purchase-no surprises, just professional quality; the preview below is taken directly from the full report you'll get, and once purchased the complete, editable version is unlocked for immediate download.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eO\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003epportunities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Opportunities-Sun-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExpansion into Non-Dialysis Markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eConducting trials to expand Vafseo's label into non-dialysis chronic kidney disease (CKD) could raise the addressable US anemia market from ~1.2M dialysis patients to ~6-8M non-dialysis CKD patients, per 2024 CDC and Kidney Disease Improving Global Outcomes data, potentially multiplying peak sales several-fold versus current ~$300-400M annual erythropoiesis-stimulating agent segments; success would drive long-term revenue and position Akebia as a leader across all CKD stages.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Opportunities-Sun-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInternational Market Penetration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eWith Vafseo approved in Japan (2024) and Europe (EMA 2025), Akebia can target untapped markets in Asia and Latin America where CKD populations exceed 200 million; securing approvals in China and Brazil could add $300-500M peak annual sales based on Asia Pacific dialysis market growth of 6% CAGR to 2030.\u003c\/p\u003e\n\u003cp\u003eLocal licensing or JV deals would lower market-entry costs; a 2025 Oxbridge Pharma report shows regional partners cut commercial spend by ~35%, speeding launch by 12-18 months and diversifying revenue away from the U.S.\u003c\/p\u003e\n\u003cp\u003eGeographic expansion also hedges reimbursement risk: U.S. Medicare covers ~70% of dialysis costs, so growing ex-US sales to 30-40% of revenue would materially reduce dependence on U.S. policy shifts.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Opportunities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Opportunities-Sun-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePipeline Diversification through HIF Biology\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAkebia can leverage its HIF (hypoxia-inducible factor) biology to expand beyond anemia into acute kidney injury and ischemic diseases, where global AKI incidence reached ~13.3 million cases in 2022 and 1.7 million deaths (Lancet, 2023).\u003c\/p\u003e\n\u003cp\u003eInvesting $50-100M in early-stage R\u0026amp;D over 3-5 years could plausibly yield 2-3 new IND candidates, offering a second product wave vs current reliance on vadadustat revenue.\u003c\/p\u003e\n\u003cp\u003eShifting to a platform model could raise enterprise value materially; biotech peers with platform strategies trade at 2-4x higher EV\/revenue multiples as of 2025.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Opportunities-Sun-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic M\u0026amp;A or Licensing Deals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAkebia (Nasdaq: AKBA) could attract acquisition from a larger pharma seeking renal assets; global CKD (chronic kidney disease) drug market is projected at $18.6B in 2025, so buyers may pay a premium for Akebia's vadadustat and U.S. commercial footprint.\u003c\/p\u003e\n\u003cp\u003eOr Akebia can license in kidney therapies and use its sales force to distribute them, raising near-term revenue; Akebia reported $84.8M revenue in 2024, which could fund pipeline expansion or deal‑making.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLarge M\u0026amp;A pool: $18.6B CKD market (2025)\u003c\/li\u003e\n\u003cli\u003eAkebia revenue: $84.8M (2024)\u003c\/li\u003e\n\u003cli\u003eExit path: acquisition premium or licensing revenue\u003c\/li\u003e\n\u003cli\u003eScale benefit: faster nephrology market share growth\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Opportunities-Sun-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eImproved Payer Coverage and Reimbursement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAs real-world data for Vafseo (vadadustat) grows, Akebia can push for better formulary placement; payers often require 6-12 months of outcomes data to change coverage decisions.\u003c\/p\u003e\n\u003cp\u003ePreferred status with major insurers and PBMs could cut patient coinsurance by 20-40%, potentially raising script volume by 30-50% in year one.\u003c\/p\u003e\n\u003cp\u003eMarket access tactics-value dossiers, patient-assistance, outcomes contracts-are critical to capture peak sales estimates of $400-600M projected by 2028 by some analysts.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eReal-world evidence = faster formulary wins\u003c\/li\u003e\n\u003cli\u003ePreferred status → lower OOP, higher scripts\u003c\/li\u003e\n\u003cli\u003eOutcomes contracts reduce payer risk\u003c\/li\u003e\n\u003cli\u003eTarget: capture $400-600M peak sales\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Opportunities-Sun-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVadadustat Poised to Capture Large CKD Market - Potential $600M-$900M Peak Sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLarge non-dialysis CKD market: 6-8M US patients (CDC\/KDIGO 2024) could raise peak vadadustat sales vs current ~$300-400M ESA segment; ex‑US approvals (Japan 2024, EMA 2025) + China\/Brazil entry may add $300-500M peak; 2024 revenue $84.8M funds deals; platform\/R\u0026amp;D ($50-100M) could deliver 2-3 INDs; CKD drug market $18.6B (2025).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eUS non‑dialysis CKD\u003c\/td\u003e\n\u003ctd\u003e6-8M (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAkebia rev\u003c\/td\u003e\n\u003ctd\u003e$84.8M (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCKD market\u003c\/td\u003e\n\u003ctd\u003e$18.6B (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eT\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ehreats\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Threats-Storm-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntense Competition from GSK and Others\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe HIF-PH inhibitor market is crowded: GSK's Jesduvroq (approved 2023) reported $1.2B global sales in 2025, showing rapid uptake and strong payer access. Rivals typically deploy larger sales teams and marketing budgets-GSK spent $6.8B on R\u0026amp;D\/SG\u0026amp;A in 2024-giving pricing and bundling leverage. Akebia must defend share versus these entrenched players who can pressure margins and formulary placement. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Threats-Storm-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEvolving Regulatory Safety Standards\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe FDA and global regulators keep tight scrutiny on cardiovascular safety for anemia drugs; post‑marketing signals could trigger black‑box warnings or withdrawals, as seen when FDA added a boxed warning to Johnson \u0026amp; Johnson's epoetin products in 2007 and when EMA updated warnings for roxadustat in 2021 after CV event signals. Continuous oversight risks revenue: Akebia reported $72.3m product revenue in 2024, so a major label action could cut sales sharply.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Threats-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Threats-Storm-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eChanges in Dialysis Reimbursement Models\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMedicare covers about 80% of U.S. dialysis patients, so changes to ESRD reimbursement pose material risk to Akebia (Nasdaq: AKBA). Shifts toward bundled payments or revisions to the ESRD Prospective Payment System could cut per-patient revenue; a 10% cut on ~200,000 dialysis patients would shave millions from drug sales. Policy moves in 2024-25 raise near-term margin pressure and cash-flow uncertainty.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Threats-Storm-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRise of Generic or Biosimilar Alternatives\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eThe impending patent expiries for erythropoiesis-stimulating agents (ESAs) - several key ESA patents lapse 2026-2028 - likely invite lower-cost generics, pressuring Vafseo despite its novel HIF-PH inhibitor mechanism.\u003c\/p\u003e\n\u003cp\u003eCost-focused payers may favor cheaper ESAs; global ESA price declines of ~15-25% after generic entry (observed 2020-2024) suggest Akebia could face similar erosion and margin pressure.\u003c\/p\u003e\n\u003cp\u003eIf market-wide anemia drug prices drop 20% and Vafseo discounts follow, Akebia's gross margin could fall several percentage points, reducing 2025 revenue upside.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eESA patent expiries: 2026-2028\u003c\/li\u003e\n\u003cli\u003eObserved post-generic price drops: 15-25%\u003c\/li\u003e\n\u003cli\u003ePotential market price erosion scenario: ~20%\u003c\/li\u003e\n\u003cli\u003eImpact: lower gross margin, reduced 2025 revenue upside\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Threats-Storm-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMacroeconomic and Biotech Market Volatility\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eMacroeconomic downturns and biotech sentiment swings can sharply drag Akebia Therapeutics Inc (AKBA) share price and funding access; after 2022-2023 sector drawdowns, biotech IPO proceeds fell ~60% year-over-year, tightening capital for small biotechs.\u003c\/p\u003e\n\u003cp\u003eHigh US inflation (peaked 7% in 2022; ~3.4% in 2024) raises clinical trial and input costs, squeezing margins and extending cash burn.\u003c\/p\u003e\n\u003cp\u003eAkebia remains sensitive to interest rates: higher yields increase cost of debt and lower equity valuations, risking dilutive financings if markets tighten.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eBiotech IPO proceeds down ~60% vs prior year\u003c\/li\u003e\n\u003cli\u003eUS inflation ~3.4% (2024)\u003c\/li\u003e\n\u003cli\u003eHigher rates raise debt cost and dilute equity\u003c\/li\u003e\n\u003cli\u003eFunding access directly ties to investor sentiment\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Threats-Storm-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCrowded HIF‑PH race, ESA patent cliffs (2026-28) and pricing\/reimbursement squeeze\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThreats: crowded HIF‑PH field (Jesduvroq $1.2B 2025) and deep-pocket rivals; regulator CV scrutiny with precedent label actions; Medicare\/ESRD reimbursement shifts and ESA patent cliffs (2026-28) driving 15-25% post-generic price drops; macro\/financing risks-biotech IPO proceeds fell ~60% after 2022-23, US inflation ~3.4% (2024), higher rates raise dilution risk.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eRisk\u003c\/th\u003e\n\u003cth\u003eKey #\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eJesduvroq sales\u003c\/td\u003e\n\u003ctd\u003e$1.2B (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eESA patent expiries\u003c\/td\u003e\n\u003ctd\u003e2026-2028\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePost-generic price drop\u003c\/td\u003e\n\u003ctd\u003e15-25%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBiotech IPO proceeds\u003c\/td\u003e\n\u003ctd\u003e-60% (post‑2022)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"Balanced Scorecard","offers":[{"title":"Default Title","offer_id":53679370895702,"sku":"akebia-swot-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1027\/3715\/0294\/files\/akebia-swot-analysis.webp?v=1778874687","url":"https:\/\/balancedscorecardexamples.com\/products\/akebia-swot-analysis","provider":"Balanced Scorecard","version":"1.0","type":"link"}